reaction product of cocoalkyldiethanolamides and cocoalkylmonoglycerides and molybdenumtrioxide (1.75-2.2: 0.75-1.0:0.1-1.1)

Endpoint summary

Key value for chemical safety assessment

Genetic toxicity in vitro

Description of key information

The Chromosome Aberration, Mouse Lymphoma and both Ames studies all produced a negative result for genetic toxicity.

Link to relevant study records

Reference

Endpoint:

in vitro gene mutation study in mammalian cells

Remarks:

Type of genotoxicity: gene mutation

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: Study conducted according to OECD Guideline under GLP conditions.

Qualifier:

according to guideline

Guideline:

OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)

GLP compliance:

yes

Type of assay:

mammalian cell gene mutation assay

Target gene:

thymidine kinase, TK +/-, locus of the L5178Y mouse lymphoma cell line

Species / strain / cell type:

mouse lymphoma L5178Y cells

Metabolic activation:

with and without

Metabolic activation system:

S9 mix

Test concentrations with justification for top dose:

Experiment 1: 0, 5, 10, 20, 40, 60 ug/ml (4hr exposure without S9 activation)
Experiment 1: 0, 10, 20, 40, 80, 160 ug/ml (4hr exposure with S9 activation)
Experiment 2: 0, 2.5, 5, 10, 20, 30, 40 ug/ml (24 hr exposure without S9 activation)
Experiment 2: 0, 20, 40, 80, 160, ug/ml (24 hr exposure with S9 activation)

Vehicle / solvent:

DMSO

Untreated negative controls:

yes

Negative solvent / vehicle controls:

yes

Remarks:

DMSO

Positive controls:

yes

Positive control substance:

ethylmethanesulphonate

Remarks:

Migrated to IUCLID6: at 400 and 150 ug/ml for Experiment 1 and 2, respectively (without activation)

Positive controls:

yes

Positive control substance:

cyclophosphamide

Remarks:

Migrated to IUCLID6: at 2 and 1 ug/ml in Experiments 1 and 2, respectively (with activation)

Evaluation criteria:

The normal range for mutant frequency per survivor is 50 -200 x 10(-)6 for the TK +/- locus in L5178Y cells at this laboratory. Vehicle controls must be within ranges, although minor errors in cell counting and dilution or exposure to the metabolic activation system may cause this to be slightly elevated. Experiments where the vehicle control values are markedly greater than 200 x 10(-)6 mutant frequency per survivor are not normally acceptable and will be repeated. Positive controls should give significant increases in mutant frequency per survivor over the negative controls or at least a three to five fold but preferably 10 fold difference.

For the test material be considered to give a significant result, two or more of the following criteria must be met: A greater than three fold increase in the mutant frequency per survivor over the negative control value; a dose-related increase in the mutant frequency per survivor; an increase in the absolute number of mutants. The test result may be reported as equivocal if only one of the above criteria are met. Small statistical increases designated by the UKEMS statistical package will be reviewed using the above criteria and may be disregarded at the Study Director's discretion.

Statistics:

Calculation of the % Relative Suspension Growth (RSG) was performed along with Calculation of the Plating Efficiency (P.E.). The Calculation of Mutant Frequency was determined. The experimental data were analysed using a dedicated computer program which follows the statistical guidelines recommended by UKEMS.

Species / strain:

mouse lymphoma L5178Y cells

Metabolic activation:

with and without

Genotoxicity:

negative

Cytotoxicity / choice of top concentrations:

cytotoxicity

Vehicle controls validity:

valid

Untreated negative controls validity:

not examined

Positive controls validity:

valid

Additional information on results:

Experiment 1: There was evidence of toxicity following exposure to the test material in both the presence and absence of metabolic activation, as indicated by the decrease in % RSG and RTG values. Optimum levels of toxicity were not achieved in the absence or presence of metabolic activation due to the steep toxicity of the test material. The toxicity observed at 60 ug/ml in the absence of metabolic activation exceeded the upper acceptable limit of 90%, therefore., this dose was excluded from the statistical analysis. The excessive toxicity observed at 80 ug/ml in the absence of activation and 240 ug/ml in the presence of activation resulted in these dose levels not being plated for viability or TFT resistance. Vehicle and positive controls were within normal limits. The test material did not induce any statistically significant or dose related (linear trend) increases in the mutant frequency x 10(-)6 per viable cell in either the presence or absence of metabolic activation. No precipitate of the test material was observed at any dose level.

Experiment 2: There was evidence of a dose-related reduction in %RSG and RTG values in cultures dosed with the test material in both of the exposure groups. There was no evidence of a reduction in Day 2 (%V) viability, therefore, indicating that no residual toxicity occurred in either the absence or presence of metabolic activation. The excessive toxicity observed at 200 ug/ml and above in the presence of metabolic activation resulted in these dose levels not being plated out for viability or TFT resistance. Both positive controls induced acceptable reductions in both the %RSG value and Day 2 (%V) viabilities and RTG values. Vehicle and positive controls were within normal limits. The test material did not induce any statistically significant or dose related increases in the mutant frequency in either the presence or absence of metabolic activation.

Remarks on result:

other: all strains/cell types tested

Remarks:

Migrated from field 'Test system'.

Conclusions:

Interpretation of results (migrated information):
negative

In an OECD 476 study Molyvan 855 did not induce any toxicologically significant increases in the mutant frequency at the TK +/- locus in L5178Y cells and is therefore considered to be non-mutagenic under the conditions of the test.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed (negative)

Additional information

Additional information from genetic toxicity in vitro:

In vitro bacterial mutation:

Key study

In an OECD 471 and OECD 472 study, conducted according to GLP, Molyvan 855 is negative for bacterial reverse mutation in S. typhimurium strains TA 1535, TA 1537, TA 98 and TA 100, and E. coli WP2 uvr A, with and without metabolic activation (S-9 mix). Molyvan 855, therefore, is considered non-mutagenic in bacterial cells. (Safepharm, 1997)

Supporting study

In an OECD 471 study, conducted according to GLP, Molyvan 855 is negative for bacterial reverse mutation in S. typhimurium strains TA 1535, TA 1537, TA 98 and TA 100 and TA 1538, with and without metabolic activation (S-9 mix). Molyvan 855, therefore, is considered non-mutagenic in bacterial cells. (Microbiological Associates, 1995)

In vitro Chromosome Aberration:

Key study

In an OECD 473 study, conducted according to GLP, Molyvan 855 (oil free) did not induce a toxicologically significant increase in the frequency of cells with chromosome aberrations or polyploid cells in either the presence or absence of liver enzyme metabolizing system, Molyvan 855 (oil free) is therefore considered to be non-clastogenic to human lymphocytes in vitro (Safepharm, 1998).

In vitro mutation in mammalian cells:

Key study

In an OECD 476 study Molyvan 855 did not induce any toxicologically significant increases in the mutant frequency at the TK +/- locus in L5178Y cells and is therefore considered to be non-mutagenic under the conditions of the test.(Safepharm, 2004)

Justification for selection of genetic toxicity endpoint
OECD, GLP study.

Justification for classification or non-classification

In accordance with Regulation No 1272/2008 Table 3.5.1, based on available data on Molyvan 855 is not classified for genotoxicity according to CLP.